Marshall Wace North America L.P. purchased a new stake in shares of HCP, Inc. (NYSE:HCP) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 135,566 shares of the real estate investment trust’s stock, valued at approximately $4,203,000.
Other large investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of HCP during the fourth quarter valued at approximately $136,835,000. JPMorgan Chase & Co. raised its stake in shares of HCP by 22.9% in the first quarter. JPMorgan Chase & Co. now owns 22,920,793 shares of the real estate investment trust’s stock valued at $716,963,000 after buying an additional 4,264,935 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of HCP by 19.0% in the first quarter. Bank of New York Mellon Corp now owns 13,164,759 shares of the real estate investment trust’s stock valued at $411,794,000 after buying an additional 2,100,896 shares during the last quarter. Capital Fund Management S.A. raised its stake in shares of HCP by 509.6% in the first quarter. Capital Fund Management S.A. now owns 1,316,338 shares of the real estate investment trust’s stock valued at $41,175,000 after buying an additional 1,100,408 shares during the last quarter. Finally, APG Asset Management US Inc. raised its stake in shares of HCP by 80.4% in the first quarter. APG Asset Management US Inc. now owns 2,405,118 shares of the real estate investment trust’s stock valued at $75,232,000 after buying an additional 1,072,120 shares during the last quarter. Institutional investors own 88.98% of the company’s stock.
Shares of HCP, Inc. (NYSE HCP) traded up 0.49% during mid-day trading on Tuesday, reaching $33.00. 947,846 shares of the company were exchanged. HCP, Inc. has a 12 month low of $27.61 and a 12 month high of $40.43. The firm has a 50-day moving average price of $31.32 and a 200 day moving average price of $30.85. The stock has a market capitalization of $15.46 billion, a P/E ratio of 15.91 and a beta of 0.42.
HCP (NYSE:HCP) last issued its earnings results on Tuesday, May 2nd. The real estate investment trust reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.03. HCP had a net margin of 41.38% and a return on equity of 12.39%. The firm had revenue of $492.16 million during the quarter, compared to the consensus estimate of $514.82 million. During the same quarter in the prior year, the firm earned $0.69 earnings per share. The business’s quarterly revenue was down 5.4% on a year-over-year basis. Equities research analysts anticipate that HCP, Inc. will post $1.45 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, May 23rd. Shareholders of record on Monday, May 8th were paid a $0.37 dividend. This represents a $1.48 annualized dividend and a yield of 4.51%. The ex-dividend date was Thursday, May 4th. HCP’s payout ratio is presently 72.20%.
TRADEMARK VIOLATION NOTICE: This article was posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thestockobserver.com/2017/06/20/marshall-wace-north-america-l-p-purchases-shares-of-135566-hcp-inc-hcp.html.
A number of research analysts recently commented on HCP shares. Evercore ISI upgraded shares of HCP from an “underperform” rating to an “in-line” rating in a research note on Monday, March 27th. They noted that the move was a valuation call. Bank of America Corporation upgraded shares of HCP from a “neutral” rating to a “buy” rating and raised their price objective for the company from $33.25 to $35.00 in a research note on Monday, April 3rd. Morgan Stanley upgraded shares of HCP from an “underweight” rating to an “equal weight” rating and set a $31.00 price objective on the stock in a research note on Monday, March 20th. Mizuho lowered shares of HCP from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $34.00 to $32.00 in a research note on Tuesday, April 11th. Finally, Robert W. Baird started coverage on shares of HCP in a research note on Friday, March 10th. They set a “neutral” rating and a $32.00 price objective on the stock. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and three have issued a buy rating to the company. HCP currently has a consensus rating of “Hold” and an average target price of $33.18.
In other HCP news, insider Thomas Klaritch sold 2,651 shares of the company’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $31.53, for a total value of $83,586.03. Following the completion of the sale, the insider now owns 176,830 shares of the company’s stock, valued at $5,575,449.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.22% of the stock is currently owned by corporate insiders.
HCP, Inc is a self-administered real estate investment trust. The Company invests in real estate serving the healthcare industry in the United States. The Company’s segments include senior housing triple-net (SH NNN), senior housing operating portfolio (SHOP), life science and medical office. Its senior housing facilities include independent living facilities, assisted living facilities, memory care facilities, care homes, and continuing care retirement communities.
Receive News & Ratings for HCP Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP Inc. and related companies with MarketBeat.com's FREE daily email newsletter.